You may have already seen this on Forbes. On March 11, the FDA approved the combination of Pegintron (Peginterferon alfa-2b) and Rebetrol (ribavirin) for treating chronic hepatitis C in patients 3 years of age and older with compensated liver disease. This is now the first and only pegylated interferon combination therapy approved in the United States that is not restricted to treatment-naive patients. Treatment to this combination is often dependent on your type of hepatits C virus genotype. There is such a need for better therapies for patients with chronic hepatitis C in this country. So many people got infected by blood transfusions before 1992 when the medical community didn't know about hepatitis C.
Pegintron is manufactured by Schering-Plough. If Schering-Plough merges with Merck, then the new company will be called Merck, so things may get a bit confusing.